Acclarent, Inc.
TypeSubsidiary
IndustryHealth Care
Founded2004 (2004)
HeadquartersIrvine, CA, United States
Key people
Jeff Hopkins, CEO
Joshua Makower, Co-Founder
John Chang, Co-Founder
ProductsRelieva Balloon Sinuplasty Systems
Number of employees
300
ParentEthicon Inc.
Websiteacclarent.com

Acclarent, Inc. began as a privately held, venture-backed company, and is now a subsidiary of Johnson & Johnson. It is based in Irvine, Orange County, California.[1] Acclarent develops technology for ENT (Ear, Nose and Throat) related illnesses.

History

Acclarent was founded in 2004. The company has over 300 employees and operates in more than 45 countries. Acclarent’s corporate headquarters are located in the Silicon Valley in Menlo Park, California. Since inception, Acclarent has reported more than $103.5M in funding from its venture partners, New Enterprise Associates (NEA), Versant Ventures, Delphi Ventures, Meritech Capital Partners, and Johnson & Johnson Development Corporation.[2]

Acclarent was founded by Joshua Makower[3] who currently serves as Acclarent’s Chairman of the Board. William M. Facteau was the company's President and Chief Operating Officer from November 2004 until March 2012. The company's president is currently Jeff Hopkins.

In May 2005, Acclarent received FDA approval[4] for its Relieva Balloon Sinuplasty technology. The company’s portfolio has more than 40 FDA-approved devices including the Relieva Balloon Sinuplasty systems, comprising the Relieva Ultirra sinus balloon catheters, the Relieva Luma sinus illumination guidewires, the Relieva Vortex which provides deep intra-sinus fluid delivery and strong shear flows to empty sinus contents, and the Cyclops articulating endoscope.[5]

In January 2010, Ethicon Inc., a Johnson & Johnson company, completed the acquisition of Acclarent.[6]

In September 2017, Acclarent received FDA clearance for the Aera balloon, the first ever device to treat chronic eustachian tube dysfunction.

In December 2023, Integra LiveSciences announced they were acquiring Acclarent for $275m. [7]

References

  1. ↑ "Acclarent files for initial public offering". Boston Globe. 2008-06-06. Archived from the original on 2009-05-05. Retrieved May 5, 2009.
  2. ↑ "About Us".
  3. ↑ "Balloon Therapy". Forbes. 2006-05-22.
  4. ↑ "ACCLARENT INC - Securities Registration Statement (S-1) SUMMARY".
  5. ↑ "Balloon Sinuplasty Technology by Acclarent | Products". Archived from the original on 2009-06-01. Retrieved 2009-05-05.
  6. ↑ "Ethicon Completes Acquisition of Acclarent | Ethicon". www.ethicon.com. Archived from the original on 2010-06-18.
  7. ↑ "Integra LifeSciences Announces Definitive Agreement To Acquire Acclarent".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.